Monash IVF Group Limited announced the Managing Director and CEO, Mr. James Thiedeman has tendered his resignation to take up a leadership role in a non-competing unlisted health care organisation outside the women's health sector with international growth plans. The Board of Monash IVF Group Limited and Mr. Thiedeman have agreed he will work through his six month notice period and remain with the Company for the release of the company's full year financial results for 2017. During this time, Mr. Thiedeman will support the business and work with the Board to ensure a smooth transition to the new Managing Director and CEO.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 AUD | +0.75% | -4.93% | +3.85% |
Apr. 30 | Wilsons Upgrades Monash IVF to Overweight from Market-Weight, Price Target is AU$1.58 | MT |
Apr. 12 | RBC Capital Markets Starts Monash IVF Group at New Sector Perform, Price Target is AU$1.50 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.85% | 347M | |
+24.47% | 88.24B | |
-23.13% | 76.2B | |
+1.41% | 26.63B | |
+8.98% | 18.14B | |
-12.89% | 16.69B | |
+3.49% | 15.85B | |
+76.87% | 13.61B | |
+79.38% | 13.24B | |
+38.44% | 12.72B |
- Stock Market
- Equities
- MVF Stock
- News Monash IVF Group Limited
- Monash IVF Group Limited Announces Resignation of James Thiedeman as CEO and Managing Director